Forum Alert: Pharmos Corporation will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor For
June 09 2005 - 8:30AM
Business Wire
Pharmos Corporation (NasdaqSC: PARSD) will present at the following
forum: -0- *T What: Informed Investors Biotechnology / Healthcare /
Pharmaceutical Investor Forum When: June 15, 2005 @ 2:35 PM Eastern
Time Sponsors: Barron's, The Wall Street Journal, The American
Stock Exchange and Business Wire Keynote Presentations: Lynn
Sutherland, M.S., M.B.A. - President, Sutherland Consulting Dr.
Navdeep Jaikaria, Senior Biotechnology Analyst, Rodman &
Renshaw, LLC Where: The Princeton Club of New York, 15 West 43rd
Street., New York City, NY 10036 How to attend: Pre-registration is
necessary. To register, contact Cary Loeser, cloeser@wilink.com, or
804-327-3407. You may also call Customer Service at 888-301-6618,
or register at the following link:
http://www.informedinvestors.com/CustomEvent/89559/index.asp If you
are unable to attend the live event, the forum will be available
via webcast at
http://www.informedinvestors.com/CustomEvent/89559/index.asp
Contact: Gale Smith, Gale.Smith@pharmos-us.com, 732-452-9556 X204
*T Pharmos discovers and develops novel therapeutics to treat a
range of indications, in particular neurological and inflammatory
disorders. The Company's core proprietary technology platform
focuses on discovery and development of synthetic cannabinoid
compounds. Cannabinor, the lead CB2-selective receptor agonist
candidate, is scheduled to begin Phase I safety studies in the
second half of 2005 and, if successful, enter Phase II testing in
pain indications around yearend or early 2006. From the
dextrocannabinoid family, the neuroprotective drug candidate
dexanabinol recently completed a Phase IIa trial as a preventive
agent against post-surgical cognitive impairment. Other compounds
from Pharmos' proprietary synthetic cannabinoid library are in
pre-clinical studies targeting pain, multiple sclerosis, rheumatoid
arthritis and other disorders.
Pharmos (NASDAQ:PARSD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharmos (NASDAQ:PARSD)
Historical Stock Chart
From Jul 2023 to Jul 2024